| 选择性M3受体拮抗剂的研究进展 |
| |
| 引用本文： | 康从民,吕英涛,代英杰,马明建,王伟宁.选择性M3受体拮抗剂的研究进展[J].化学通报,2012(4):312-317. |
| |
| 作者姓名： | 康从民 吕英涛 代英杰 马明建 王伟宁 |
| |
| 作者单位： | 青岛科技大学化工学院 |
| |
| 基金项目： | 国家自然科学基金项目(21072111);山东省自然科学基金项目(ZR2011BM015);山东省高等学校科技计划项目(J07YC08,J09LC20)资助 |
| |
| 摘 要： | M3受体是毒蕈碱型乙酰胆碱受体的亚型之一,在人体内分布广泛。选择性M3受体拮抗剂可以竞争性地与M3受体结合,主要用于膀胱过度活动症(OAB)、慢性阻塞性肺病(COPD)和肠道易激综合症(IBS)等疾病的治疗。与非选择性拮抗剂相比,选择性M3受体拮抗剂对中枢神经以及心脏的副作用大大降低。本文对已上市及处在不同研究阶段的选择性M3受体拮抗剂进行了综述。
|
| 关 键 词： | M3受体 拮抗剂 结构改造 选择性 |
Progress of Selective M3 Receptor Antagonists |
| |
| Kang Congmin,Lv Yingtao,Dai Yingjie,Ma Mingjian,Wang Weining.Progress of Selective M3 Receptor Antagonists[J].Chemistry,2012(4):312-317. |
| |
| Authors: | Kang Congmin Lv Yingtao Dai Yingjie Ma Mingjian Wang Weining |
| |
| Institution: | (College of Chemical Engineering,Qingdao University of Science and Technology,Qingdao 266042) |
| |
| Abstract: | M3 receptor is one of the most important muscarinic acetylcholine sub-type receptors,and is widely distributed in the human body.Selective M3 receptor antagonists can competitively bind to M3 receptors.It is used to treat Overactive Bladder(OAB),Chronic Obstructive Pulmonary Disease(COPD),Irritable Bowel Syndrome(IBS) and other Diseases.The side effects on central nervous system and heart of selective M3 receptor antagonists are greatly reduced compared with non-seleotive antagonists.The progress of selective M3 receptor antagonists was reviewed in this paper. |
| |
| Keywords: | M3 receptor Antagonist Structural modification Selectivity |
| 本文献已被 CNKI 等数据库收录！ |
|
